Abbreviated Name

LTP2 Results Analysis-Hanash-MDACC 2024

Lead Investigator

Hanash, Samir — The University of Texas MD Anderson Cancer Center

Coordinating Investigator

Zheng, Yingye — Fred Hutchinson Cancer Center

Involved Investigators

• Hanash, Samir — The University of Texas MD Anderson Cancer Center
• Zheng, Yingye — Fred Hutchinson Cancer Center

Abstract

See objectives

Aims

Aim 1) Measuring the positive and negative predictive value of the 4MP in the LTP2 indeterminate nodule cohort. Preliminary data indicates that the 4MP can help distinguish benign from malignant pulmonary nodules, with notable performance in increasing sensitivity at high specificity over clinical measures of nodule risk. We will evaluate if the 4MP performs similarly in this dataset to identify malignant nodules. Additionally, as LTP2 samples will be analyzed by other EDRN groups, it will provide an opportunity to measure head-to-head performance of the 4MP with other biomarker candidates. We have received over 200 samples from individuals with nodules from the EDRN LTP2 cohort. We are currently awaiting access to these CT images from the JPL repository. We will also perform radiomics on the CT scans to develop a composite classifier. With co-PI Dr Wilson, along with Dr Matt Schabath (Moffitt) and Dr Michael Kammer (Vanderbilt) are working to form a radiomics subgroup within the lung group of the EDRN. Aim 2) Blood-based biomarkers to refine eligibility and to improve clinical workflow in LCS. We have already received 1390 NLST plasma samples, including 135 samples taken from individuals in the CT screening arm with negative CTs taken within 12 months and 143 samples from individuals with pulmonary nodules diagnosed as cancer, matched 1:4 with control samples (675 + 715 samples). We are requesting additional cohorts of samples, including additional control samples, plasma samples of lung cancer cases and non-cases from the chest radiography arm, as well as longitudinally collected samples from the CT arm:

Analytic Method

Analyzed by the DMCC

Comments

First analysis did not perform well. No manuscript planned. Second analysis TBD

Outcome

Aim 1) Measuring the positive and negative predictive value of the 4MP in the LTP2 indeterminate nodule cohort. Preliminary data indicates that the 4MP can help distinguish benign from malignant pulmonary nodules, with notable performance in increasing sensitivity at high specificity over clinical measures of nodule risk. We will evaluate if the 4MP performs similarly in this dataset to identify malignant nodules. Additionally, as LTP2 samples will be analyzed by other EDRN groups, it will provide an opportunity to measure head-to-head performance of the 4MP with other biomarker candidates. We have received over 200 samples from individuals with nodules from the EDRN LTP2 cohort. We are currently awaiting access to these CT images from the JPL repository. We will also perform radiomics on the CT scans to develop a composite classifier. With co-PI Dr Wilson, along with Dr Matt Schabath (Moffitt) and Dr Michael Kammer (Vanderbilt) are working to form a radiomics subgroup within the lung group of the EDRN. Aim 2) Blood-based biomarkers to refine eligibility and to improve clinical workflow in LCS. We have already received 1390 NLST plasma samples, including 135 samples taken from individuals in the CT screening arm with negative CTs taken within 12 months and 143 samples from individuals with pulmonary nodules diagnosed as cancer, matched 1:4 with control samples (675 + 715 samples). We are requesting additional cohorts of samples, including additional control samples, plasma samples of lung cancer cases and non-cases from the chest radiography arm, as well as longitudinally collected samples from the CT arm:

Publications

• No publications available at this time for this protocol.

Biomarkers

• No biomarkers available at this time for this protocol.

Data Collections

• No data collections available at this time for this protocol.

 Team Project

Start Date

May 5 2023

Estimated Finish Date

Nov 5 2023

Finish Date

Aug 7 2024

Protocol ID

547

Protocol Type

Reference Set

Fields of Research

• Genomics
• Proteomics

Collaborative Group

Lung and Upper Aerodigestive Cancers Research Group

Cancer Types

• Malignant neoplasm of bronchus and lung

Phased Status

2